Image credits: Aidence
RadNet Inc, a provider of outpatient diagnostic imaging services, announced on Monday that it has acquired two Dutch technology companies – Quantib and Aidence – for an undisclosed amount.
Based out of Rotterdam, Quantib is a radiology AI company that focuses on clinical solutions for prostate cancer, breast cancer and neurodegeneration. Aidence is an Amsterdam-based startup that focuses on clinical solutions for pulmonary nodule management and lung cancer screening.
Get to know the amazing finalists here
Acquisition
The two acquisitions enable RadNet to offer widespread cancer screening programs for the three most prevalent cancers – breast, prostate and lung – by complementing RadNet’s existing DeepHealth mammography AI division
The acquisitions will also cement RadNet’s leadership position in the development and deployment of AI to improve the care and health of patients.
As a part of the acquisitions, Aidence and Quantib will join RadNet’s AI division, which to date has focused solely on breast cancer screening and detection.
Aidence: What you need to know
Founded by Jeroen van Duffelen and Mark-Jan Harte in 2015, Aidence uses Artificial Intelligence to help medical professionals detect diseases such as lung cancer.
The startup developed a solution called Veye Lung Nodules, which assists radiologists in diagnosing and tracking developments at the pulmonary nodule level to improve reporting in the treatment of lung cancer.
Aidence analyses thousands of CT scans each week, with customers in seven European countries, including France, the Netherlands and the UK.
Mark-Jan Harte, co-founder and CEO of Aidence, says, “The Aidence team, my co-founder, Jeroen, and I are all enthusiastic about joining forces with the RadNet experts. RadNet is a strong leader in medical imaging. Together, we will accelerate our growth and innovation pipeline to serve clinicians with automated and integrated AI solutions for the oncology pathway.”
“Our vision as Aidence is that data is key to improving the prevention, management, and treatment of disease. As a result of an operation of 350 facilities in some of the busiest US markets and performing over eight million exams per year, RadNet’s database of images and radiologist reports is one of the largest and most diverse we’ve identified so far,” he adds.
Quantib: What you need to know
Founded in 2012 as a spin-off of the Erasmus Medical Centre in Rotterdam, Quantib has multiple AI-based solutions, including Quantib Prostate for analysis of prostate MR images and Quantib ND to quantify brain abnormalities on MRI.
The company’s solutions are deployed through its AI Node platform for seamless workflow integration. The company has customers in more than 20 countries worldwide, including the United States.
Arthur Post Uiterweer, CEO of Quantib, says, “We are thrilled to join the RadNet family. Quantib aims to enable more accurate and efficient clinical decision-making for 10 million patients by 2030. Being part of RadNet enables us to take a major step towards this goal. Our products, which are already received very well by customers, will see a tremendous boost in performance over the coming years to the benefit of all of our rapidly expanding global user base.”
The full management, including Arthur Post Uiterweer (CEO), Jorrit Glastra (CTO) and Quirine van Voorst (COO), will stay onboard with Quantib.
RadNet Inc: What you need to know
Based out of Los Angeles, RadNet, Inc. is the national provider of freestanding, fixed-site diagnostic imaging services in the United States.
The company has a network of more than 350 owned and/or operated outpatient imaging centres. RadNet’s markets include California, Arizona, Maryland, Delaware, Florida, New Jersey, and New York.
The company also provides radiology information technology solutions, teleradiology professional services, and other related products and services to customers in the diagnostic imaging industry. At present, RadNet employs around 9,000 people.
Dr. Howard Berger, Chairman and Chief Executive Officer of RadNet, says, “We remain convinced that artificial intelligence will have a transforming impact on diagnostic imaging and the field of radiology. Upon this acquisition, we will have effective screening solutions for two of the top four most prevalent cancers. We believe that large population health screening will play an important role for health insurers, health systems, and large employer groups in the near future. As the largest owner of diagnostic imaging centres in the United States, RadNet has relationships that can serve to make large-scale screening programs, similar to what mammography is for breast cancer screening, a reality.”
How partnering up with Salesforce helped him succeed!
